MARKET

IMMP

IMMP

Immutep
NASDAQ
2.330
-0.060
-2.51%
After Hours: 2.390 +0.06 +2.58% 16:50 03/28 EDT
OPEN
2.400
PREV CLOSE
2.390
HIGH
2.466
LOW
2.300
VOLUME
112.43K
TURNOVER
0
52 WEEK HIGH
3.900
52 WEEK LOW
1.500
MARKET CAP
277.00M
P/E (TTM)
-8.6875
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMMP last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at IMMP last week (0311-0315)?
Weekly Report · 03/18 10:17
Weekly Report: what happened at IMMP last week (0304-0308)?
Weekly Report · 03/11 10:16
Analyst Issues Buy Rating on Immutep Stock Amid Promising Efti Drug Trial Results
TipRanks · 03/07 05:00
Immutep: Report of foreign issuer
Press release · 03/06 12:00
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Immutep Limited announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha in combination with weekly paclitaxel. The drug is being tested in a Phase 2/3 trial of breast cancer patients. No serious adverse events were reported.
Benzinga · 03/05 20:57
Immutep Announces First Clinical Data From 90mg Dosing Of Efti
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated. Encouraging initial efficacy in six metastatic breast cancer patients, demonstrated by a 50% overall response rate, and a 100% disease control rate.
Benzinga · 03/05 13:12
Weekly Report: what happened at IMMP last week (0226-0301)?
Weekly Report · 03/04 10:18
More
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.